Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.

(b) On April 19, 2023, Nicholas Laccona, Principal Financial and Accounting Officer of Bellerophon Therapeutics, Inc. (the "Company"), notified the Company of his intent to resign as Principal Financial and Accounting Officer and from all other positions held with the Company. The Company and Mr. Laccona are currently negotiating the effective date of his resignation.


                                       2

© Edgar Online, source Glimpses